Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Sees Strong Trading Volume

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) shares saw unusually-strong trading volume on Monday . Approximately 1,004,975 shares were traded during mid-day trading, an increase of 247% from the previous session’s volume of 289,970 shares.The stock last traded at $0.95 and had previously closed at $0.89.

A number of equities research analysts recently weighed in on NAVB shares. Maxim Group set a $2.00 price target on shares of Navidea Biopharmaceuticals and gave the company a “buy” rating in a report on Friday, August 9th. HC Wainwright assumed coverage on Navidea Biopharmaceuticals in a research note on Friday, November 22nd. They set a “buy” rating and a $3.00 target price for the company.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.17). The business had revenue of $0.24 million during the quarter.

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

See Also: Price-Sales Ratio

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.